Blood Cancer Drugs Global Market Research Report 2022: Blood Cancer Type, Drugs, Treatment Approaches – Forecasts to 2026 & 2031 – ResearchAndMarkets.com

Blood Cancer Drugs Global Market Research Report 2022: Blood Cancer Type, Drugs, Treatment Approaches – Forecasts to 2026 & 2031 – ResearchAndMarkets.com




Blood Cancer Drugs Global Market Research Report 2022: Blood Cancer Type, Drugs, Treatment Approaches – Forecasts to 2026 & 2031 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Blood Cancer Drugs Global Market Report 2022, Blood Cancer Type, Drugs, Treatment Approaches” report has been added to ResearchAndMarkets.com’s offering.

The global blood cancer drugs market is expected to grow from $54.83 billion in 2021 to $61.26 billion in 2022 at a compound annual growth rate (CAGR) of 11.7%. The market is expected to reach $89.75 billion in 2026 at a CAGR of 10.0%.

Major players in the blood cancer drugs market are Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Johnson & Johnson, Novartis, Pfizer Inc, AbbVie Inc. and Takeda Pharmaceutical Company Ltd.

The blood cancer drugs market consists of sales of drugs to treat all types of blood cancers. The blood cancer drugs market excludes biologics and includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating leukaemia, lymphoma, and myeloma.

The main types of blood cancer drugs are leukemia, and lymphoma. Leukemia is a blood-forming tissue cancer that affects the bone marrow and lymphatic tract. The different types of drugs include rituaxan/mabthera (rituximab), gleevac/glivec (imatinib), revlimid (lenalidomide), velcade (bortezomib), tasigna (nilotinib), pomalyst (pomalidomide), vidaza (azacitidine), kyprolis (carfilzomib), adcetris (brentuximab vedotin), others and involve various treatment approaches such as key findings, chemotherapeutic, mabs/targeted therapies, immunotherapeutic.

North America is the largest region in the blood cancer drugs market in 2021. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The blood cancer drugs market is being driven by the growing death incidences and increasing prevalence of blood cancer cases across the globe. Different types of blood cancers such as lymphoma, leukaemia, myeloma and others have different risk factors where some can be controlled or prevented through drug therapies and others may lead to death. According to Bristol-Myers Squibb Company report, over 1.85 million new blood cancer cases are expected to be diagnosed across the globe in 2040, out of which 918,872 cases are from lymphoma, 656,345 from leukaemia, and 275,047 cases myeloma.

Furthermore, the report estimated, in 2040, the approximate number of deaths worldwide due to blood cancer will be 1,100,000. In 2019, more than 387,000 people are living with leukaemia in the United States and 68,000 deaths resulted from blood cancer. According to national cancer institute, the deaths due to blood cancer reached around 22,840 in 2019. The increasing deaths and increasing incidence of blood cancer cases globally drives the blood cancer drug market.

Drug approval involves series of research stages and regulatory approvals that are often expensive. Drug approval process include about four phases of clinical trials and various stages of screening process with the regulatory body such as FDA. The costs of failed clinical trials are also high as clinical trial phases involves huge investments. According to Tufts Centre for the Study of Drug Development, the cost of bringing a new drug from its conception to shelves is about $2.7 billion. Thus indicating that the high drug approval costs hinders the growth of the blood cancer drugs market.

Companies in the blood cancer drugs market are increasingly investing in technologies such as artificial intelligence (AI) to save time and reduce research and development costs. AI is the simulation of human intelligence processes by machines, especially computer systems, which has the potential to surpass human intelligence levels. This technology helps to analyse large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis.

The technology also helps in speeding up the patient recruitment process by matching blood cancer patients with the most relevant clinical trials, thus lowering clinical trial costs. Major blood cancer drug manufacturers such as Roche, Pfizer and Johnson and Johnson have already invested in AI technologies to reduce time taken and costs incurred for drug development. For instance, Johnson and Johnson entered into an agreement with BenevolentAI, a UK-based artificial intelligence company (start-up), to mine data for designing new blood cancer drugs.

The Food and Drug Administration (FDA) is a federal agency regulating the blood cancer drugs market. In June 2019, FDA declined to approve Daiichi Sankyo’s leukaemia drug for blood cancer treatment. Daiichi Sankyo, a global pharmaceutical company developing, importing and marketing pharmaceutical products received a rejection notice on its drug – quizartinib used for treating adults with a type of blood cancer.

The rejection of drug was due to the negative impact caused after the intake which resulted in FDA’s statement saying faulty application for blood cancer treatment in an internal review. To avoid the incidences caused by such medicines in treating medical conditions such as blood cancer, FDA has declined to the approval.

Companies Mentioned

  • Amgen Inc.
  • AstraZeneca PLC.
  • Bayer AG
  • Celgene Corporation
  • Eli Lilly
  • Johnson & Johnson
  • Novartis
  • Pfizer Inc.
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Ltd.
  • F.Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Astellas Pharma Inc.
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • Merck and Company
  • Roche Holding AG

Key Topics Covered:

1. Executive Summary

2. Blood Cancer Drugs Market Characteristics

3. Blood Cancer Drugs Market Trends And Strategies

4. Impact Of COVID-19 On Blood Cancer Drugs

5. Blood Cancer Drugs Market Size And Growth

5.1. Global Blood Cancer Drugs Historic Market, 2016-2021, $ Billion

5.1.1. Drivers Of The Market

5.1.2. Restraints On The Market

5.2. Global Blood Cancer Drugs Forecast Market, 2021-2026F, 2031F, $ Billion

5.2.1. Drivers Of The Market

5.2.2. Restraints On the Market

6. Blood Cancer Drugs Market Segmentation

6.1. Global Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

  • Leukemia
  • Lymphoma

6.2. Global Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

  • Rituaxan/Mabthera (Rituximab)
  • Gleevac/Glivec (Imatinib)
  • Revlimid (Lenalidomide)
  • Velcade (Bortezomib)
  • Tasigna (Nilotinib)
  • Pomalyst (Pomalidomide)
  • Vidaza (Azacitidine)
  • Kyprolis (Carfilzomib)
  • Adcetris (Brentuximab Vedotin)
  • Others

6.3. Global Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

  • Key Findings
  • Chemotherapeutic
  • mAbs/Targeted Therapies
  • Immunotherapeutic

7. Blood Cancer Drugs Market Regional And Country Analysis

7.1. Global Blood Cancer Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

7.2. Global Blood Cancer Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

For more information about this report visit https://www.researchandmarkets.com/r/cbqn28

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900